3SOF

Golden Cross (MA 50 goes through MA 200)

watch for breakout over 2.00...nice white candle yesterday..

CAMH

In at 2.70, let see if we can bounce off tomorrow

The set-up is very interesting
---Price above 9sma & MACD bullish cross above zero (weekly chart)

I'd love to see 3.75 again, but I might settle for 3.30 if it makes there next week:

Closed above 3 bucks now ....up 13%

I sold 1/2 my position at 2.89 just before earnings.....trying to get at least 3.30 for the other 1/2, we'll see

HCSC to Cover Microvolt T-Wave Alternans Testing
Tuesday November 7, 10:07 am ET 
Largest Private Insurer in Texas, Illinois, and Oklahoma


BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB:CAMH - News) today announced that Healthcare Service Corporation ("HCSC") has revised its Coverage Policy Bulletin (MED202.006) on Microvolt T Wave Alternans agreeing to make it a covered benefit. HCSC provides healthcare benefits to 11.6 million beneficiaries through its BlueCross BlueShield divisions in Texas, Illinois, New Mexico and Oklahoma. The new policy states:



"Microvolt T-Wave Alternans (MTWA) as a technique of risk stratification for primary or secondary prevention of fatal arrhythmias and sudden cardiac death (SCD) may be considered medically necessary in patients who are at risk of developing life-threatening ventricular arrhythmias."

Quote from: bocasva on October 27, 2006, 01:05:34 PM
I'd love to see 3.75 again, but I might settle for 3.30 if it makes there next week:

Starting to get greedy here, 3.75 is within reach now....will wait to see how it closes...

CAMH to the moon!! he he he...

What are the predictions on this one?

I see 3.98 as all-time high and I would expect a huge news to break it. If phase III comes out positive and FDA approves it then it could be blue sky breakout.
I see 2 possibilities: 1. It hits 3.98 and forms a cup on 1-year chart and then retraces to form a handle..
Phase 3 results are positive and FDA approves it.. huge gap and big run to 2 digits.

What do you guys predict?

Quote from: bocasva on November 07, 2006, 01:28:27 PM

Quote from: bocasva on October 27, 2006, 01:05:34 PM
I'd love to see 3.75 again, but I might settle for 3.30 if it makes there next week:

Starting to get greedy here, 3.75 is within reach now....will wait to see how it closes...

I sold my remaining 1/2 today at 3.47.  It opened out nice, no gap, but sold it after it crossed the opening/closing price.  Will look for a re-entry price hopefully at a lower price after some consolidation.

UP WE GO AGAIN ON NEWS !!!!!!!!!

Press Release   Source: Cambridge Heart, Inc.

WellPoint To Cover Microvolt T-Wave Alternans Testing
Monday November 13, 8:39 am ET
The Largest Private Insurer in the U.S. Provides Healthcare Coverage to 34 million Individuals

BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB:CAMH - News) today announced that WellPoint/Anthem has revised its Coverage Policy Bulletin (MED.00041) on Microvolt T Wave Alternans agreeing to make it a covered benefit for its beneficiaries in California and 13 other states. The revised policy now states:

"Microvolt T-wave alternans (beat-to-beat variability in the amplitude of the T-wave) using the spectral analytic method is considered medically necessary for the evaluation of patients at risk of sudden cardiac death who meet the approved criteria for implantable cardioverter defibrillator (ICD) placement."

WellPoint's approved criteria for ICD placement addresses a comprehensive set of cardiac disease conditions well beyond the SCDHeFT patient set that is in the spotlight at this time. The policy deems MTWA medically necessary for diagnosis within the SCDHeFT population, but like Medicare and the other private carriers, WellPoint also reimburses the use of MTWA for patients with:

1. History of cardiac arrest due to ventricular fibrillation (VF) or ventricular tachycardia (VT) and which is not due to reversible or transient causes; or

2. Spontaneous sustained VT, in patients with structural heart disease; or

3. Spontaneous sustained VT, in patients without structural heart disease, that is not amenable to other treatments; or

4. Syncope of undetermined origin with clinically relevant, hemodynamically significant, sustained VT or VF induced at electrophysiological study when drug therapy is ineffective, not tolerated, or not preferred; or

5. Familial or inherited conditions with a high risk for life-threatening ventricular tachyarrhythmias such as long QT syndrome or hypertrophic cardiomyopathy; or

6. Previous myocardial infarction and coronary artery disease (CAD), at least 40 days post myocardial infarction and three months post coronary artery revascularization surgery with an ejection fraction equal to or less than 35% after maximal medical therapy; or

7. Ischemic dilated cardiomyopathy (IDCM) with NYHA Class II or III heart failure, documented prior myocardial infarction (MI), at least 40 days post MI, and measured left ventricular ejection fraction (LVEF) less than or equal to 35%; or

8. Non-ischemic dilated cardiomyopathy (NIDCM) greater than 9 months duration, NYHA Class II or III heart failure, and measured LVEF less than or equal to 35%.

"We are extremely pleased that WellPoint has decided to provide coverage for our Spectral Analytic Method Microvolt T-Wave Alternans test." said Jeff Langan, President and CEO of Cambridge Heart, Inc. "WellPoint is the largest private insurer in California and 9 other states, and coupled with its Anthem subsidiary, is a leading provider in four other states as well. The vast majority of private insurance patients in the USA are now under covered as are Medicare patients. This represents a key milestone in our objective of gaining private insurance coverage for MTWA testing."

Quote from: Terliso on November 08, 2006, 04:42:10 PM
CAMH to the moon!! he he he...

Almost there.. he he he..